Home > Insider Trading > Filing (0001562180-20-003451)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1434418	Constellation Pharmaceuticals Inc	CNST	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1246842	A Mark Goldsmith	C/O Constellation Pharmaceuticals, Inc. 215 First Street, Suite 200 Cambridge MA 02142		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-05-05	2,325	$1.55	145,388	No	4	M	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee
Common Stock	Acquisiton	2020-05-05	300	$11.50	145,688	No	4	M	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee
Common Stock	Acquisiton	2020-05-05	520	$7.60	146,208	No	4	M	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee
Common Stock	Disposition	2020-05-05	3,145	$40.01	143,063	No	4	S	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee
Common Stock	Acquisiton	2020-05-06	6,813	$1.55	149,876	No	4	M	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee
Common Stock	Acquisiton	2020-05-06	750	$11.50	150,626	No	4	M	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee
Common Stock	Acquisiton	2020-05-06	3,900	$7.60	154,526	No	4	M	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee
Common Stock	Disposition	2020-05-06	11,463	$45.06	143,063	No	4	S	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee
No	4	M	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee
No	4	M	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee
No	4	S	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee
No	4	M	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee
No	4	M	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee
No	4	M	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee
No	4	S	Indirect	Owned by Trusts for which Mark A. Goldsmith is a Trustee

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-05-05	2,325	$0.00	2,325	$1.55
Common Stock	Stock Option (right to buy)	Disposition	2020-05-05	300	$0.00	300	$11.50
Common Stock	Stock Option (right to buy)	Disposition	2020-05-05	520	$0.00	520	$7.60
Common Stock	Stock Option (right to buy)	Disposition	2020-05-06	6,813	$0.00	6,813	$1.55
Common Stock	Stock Option (right to buy)	Disposition	2020-05-06	750	$0.00	750	$11.50
Common Stock	Stock Option (right to buy)	Disposition	2020-05-06	3,900	$0.00	3,900	$7.60

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
24,525	2021-03-10	No	4	M	Direct
7,875	2028-07-18	No	4	M	Direct
17,646	2028-03-07	No	4	M	Direct
17,712	2021-03-10	No	4	M	Direct
7,125	2028-07-18	No	4	M	Direct
13,746	2028-03-07	No	4	M	Direct

Footnotes

These trades were made pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $40.00 to $40.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $45.00 to $45.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Shares are fully vested.
This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 19, 2021.
This option was granted on March 8, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through March 8, 2021.
Shares are fully vested.